The Role of ERα and ERβ in theProstate: Insights from Genetic Models and Isoform-Selective Ligands

  • S. J. McPherson
  • S. J. Ellem
  • V. Patchev
  • K. H. Fritzemeier
  • G. P. Risbridger
Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/1)


Androgens are known regulators of the growth and differentiation of the prostate gland and are effective during development and maturity as well as in disease. The role of estrogens is less well characterized, but dual direct and indirect actions on prostate growth and differentiation have been demonstrated, facilitated via both ERα and ERβ. Previous studies using animal models to determine the role of ERβ in the prostate have been problematic due to the centrally mediated responses to estrogen administration via ERα that can lower androgen levels and lead to epithelial regression, thereby masking any direct effects on the prostate mediated by ERβ. Our alternate approach was to use the estrogen-deficient aromatase knockout (ArKO) mouse and the method of tissue recombination to provide new insight into estrogen action on prostate growth and pathology. Firstly, utilizing homo- and heterotypic tissue recombinants, we demonstrate that stromal aromatase deficiency results in the induction of hyperplasia in previously normal prostatic epithelium and that this response is the result of local changes to the paracrine interaction between stroma and epithelium. Secondly, using tissue recombination and an ERβ-specific agonist, we demonstrate that the activation of ERβ results in an anti-proliferative response that is not influenced by alterations to systemic androgen levels or activation of ERα. Finally, using intact ArKO mice this study demonstrates that the administration of an ERβ-specific agonist abrogates existing hyperplastic epithelial pathology specifically in the prostate but an ERβ-specific agonist does not. Therefore, in the absence of stromal aromatase gene expression, epithelial proliferation, leading to prostatic hypertrophy and hyperplasia, may result from a combination of androgenic stimulation of proliferation and failed activation of ERβ by locally synthesized estrogens. These data demonstrate essential and beneficial effects of estrogens that are necessary for normal growth of the prostate and distinguish them from those that adversely alter prostate growth and differentiation. This indicates the potential of antiandrogens and SERMS, as opposed to aromatase inhibitors, for the management of prostate hyperplasia and hypertrophy.


Benign Prostatic Hyperplasia Prostate Gland Estrogen Deficiency Epithelial Hyperplasia Prostate Disease 


  1. Adlercreutz CH, Goldin BR, Gorbach SL et al (1995) Soybean phytoestrogen intake and cancer risk. J Nutr 125(3 Suppl):757S–770SGoogle Scholar
  2. Adlercreutz H, Mazur W, Bartels P et al (2000) Phytoestrogens and prostate disease. J Nutr 130:658S–659SGoogle Scholar
  3. Baulieu EE (2002) Androgens and aging men. Mol Cell Endocrinol 198:41–49PubMedCrossRefGoogle Scholar
  4. Bianco JJ, Handelsman DJ, Pedersen JS et al (2002) Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology 143:4922–4933PubMedCrossRefGoogle Scholar
  5. Bianco JJ, McPherson SJ, Wang H et al (2006) Transient neonatal estrogen exposure to estrogen deficient mice (Aromatase knockout) reduces prostate weight and induces inflammation in late life. Am J Pathol 168:1869–1878PubMedCrossRefGoogle Scholar
  6. Chrisman H, Thomson AA (2006) Regulation of urogenital smooth muscle patterning by testosterone and estrogen during prostatic induction. Prostate 66:696–707PubMedCrossRefGoogle Scholar
  7. Culig Z, Hobisch A, Cronauer MV et al (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550PubMedCrossRefGoogle Scholar
  8. Cunha GR, Donjacour A (1987) Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 239:251–272PubMedGoogle Scholar
  9. Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67:417–434PubMedCrossRefGoogle Scholar
  10. De Marzo AM, Marchi VL, Epstein JL et al (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992PubMedCrossRefGoogle Scholar
  11. Ellem SJ, Schmitt JF, Pedersen JS et al (2004) Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 89:2434–2441PubMedCrossRefGoogle Scholar
  12. Gray A, Feldman HA, McKinlay JB et al (1991a) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016–1025PubMedCrossRefGoogle Scholar
  13. Gray A, Berlin JA, McKinlay JB et al (1991b) An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 44:671–684PubMedCrossRefGoogle Scholar
  14. Griffiths K (2000) Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 45:87–100PubMedCrossRefGoogle Scholar
  15. Ho S, Leav I, Merk FB et al (1995) Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. Lab Invest 73:356–365PubMedGoogle Scholar
  16. Huggins C, Hodges CV (1941) Studies on prostatic cancer. The effect of castration, of estrogen and of androgen interaction on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297Google Scholar
  17. Imamov O, Morani A, Shim GJ et al (2004) Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 101:9375–9380PubMedCrossRefGoogle Scholar
  18. Kuiper GG, Lemmen JG, Carlsson B et al (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252–4263PubMedCrossRefGoogle Scholar
  19. McPherson S, Wang H, Jones ME et al (2001) Elevated androgens and prolactin in aromatase deficient (ArKO) mice cause enlargement but not malignancy of the prostate gland. Endocrinology 142:2458–2467PubMedCrossRefGoogle Scholar
  20. Mentor-Marcel R, Lamartiniere CA, Eltoum IE et al (2001) Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61:6777–6782PubMedGoogle Scholar
  21. Nelson WG, De Marzo AM, De Weese TL et al (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6–S11; discussion S11–S2PubMedCrossRefGoogle Scholar
  22. Omoto Y, Imamov O, Warner M et al (2005) Estrogen receptor alpha and imprinting of the neonatal mouse ventral prostate by estrogen. Proc Natl Acad Sci USA 102:1484–1489PubMedCrossRefGoogle Scholar
  23. Prins GS, Birch L, Couse JF et al (2001) Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 61:6089–6097PubMedGoogle Scholar
  24. Risbridger G, Wang H, Young P et al (2001a) Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 229:432–442PubMedCrossRefGoogle Scholar
  25. Risbridger GP, Wang H, Frydenberg M et al (2001b) The metaplastic effects of estrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. Endocrinology 142:2443–2450PubMedCrossRefGoogle Scholar
  26. Shapiro E, Huang H, Masch RJ et al (2005) Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J Urol 174:2051–2053PubMedCrossRefGoogle Scholar
  27. Stephens FO (1997) Phytoestrogens and prostate cancer: possible preventive role. Med J Aust 167:138–140PubMedGoogle Scholar
  28. Thompson TC, Timme TL, Park SH et al (2000) Mouse prostate reconstitution model system: a series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43:248–254PubMedCrossRefGoogle Scholar
  29. Vermeulen A, Rubens R, Verdonck L (1972) Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 34:730–735PubMedCrossRefGoogle Scholar
  30. Vermeulen A, Kaufman JM, Goemaere S et al (2002) Estradiol in elderly men. Aging Male 5:98–102PubMedGoogle Scholar
  31. Weihua Z, Makela S, Andersson LC et al (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98:6330–6335PubMedCrossRefGoogle Scholar
  32. Wu JP, Gu FL (1987) The prostate 41–65 years post castration. An analysis of 26 eunuchs. Chin Med J (Engl) 100:271–272Google Scholar
  33. Zumoff B, Levin J, Strain GW et al (1982) Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a two-disease theory. Prostate 3:579–588PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • S. J. McPherson
    • 1
  • S. J. Ellem
    • 1
  • V. Patchev
    • 2
  • K. H. Fritzemeier
    • 2
  • G. P. Risbridger
    • 1
  1. 1.Centre for Urology ResearchMonash Institute of Medical Research, Monash UniversityVictoriaAustralia
  2. 2.Gynecology and AndrologySchering AG, BerlinBerlinGermany

Personalised recommendations